Jissy Akkarapattiakal Kuriappan, Principal Investigator, Drug Discovery at Alembic Pharmaceuticals, discusses using AI to promote drug discovery, the problem with using AI as a black box, and whether AI and ML are a worthwhile investment.

These miniature brain replicas, cultivated from patient-derived stem cells, provide a unique window into the intricacies of brain development.

Fire and Mello’s research has unlocked a powerful new therapeutic technology: silencing genes with siRNA.

Organoid models include three-dimensional (3D) cell culture systems that closely resemble in vivo organs or tissues.

Digital biomarkers are rapidly being adopted to provide quality insights into patient health. David Nobbs, Biomarker Disease Area Lead at Roche and Valentin, Data Analytics Leader at GSK share how their companies are using digital biomarkers.

Multiple myeloma (MM) remains an incurable hematologic malignancy which ultimately develops drug resistance and evades treatment. Despite substantial therapeutic advances over the past years, the clinical failure rate of preclinically promising anti-MM drugs remains substantial.

Helping unlock the promise of cellular therapies and regenerative medicines.

Positive phase III results propel innovative pherine nasal spray as potential game-changer for millions struggling with social anxiety disorder. Vistagen's novel mechanism of action sparks optimism after previous setback.

How will SmartLab development be shaped in the coming years as AI/ML integration continues to be implemented?